Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

PURPOSE: Even with statins and other lipid-lowering therapy (LLT), many patients with heterozygous familial hypercholesterolemia (heFH) continue to have elevated low-density lipoprotein cholesterol (LDL-C) levels. ODYSSEY HIGH FH (NCT01617655) assessed the efficacy and safety of alirocumab, a propro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginsberg, Henry N., Rader, Daniel J., Raal, Frederick J., Guyton, John R., Baccara-Dinet, Marie T., Lorenzato, Christelle, Pordy, Robert, Stroes, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055560/
https://www.ncbi.nlm.nih.gov/pubmed/27618825
http://dx.doi.org/10.1007/s10557-016-6685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055560/
https://www.ncbi.nlm.nih.gov/pubmed/27618825
http://dx.doi.org/10.1007/s10557-016-6685-y

Ejemplares similares